Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation.

Microtubule-associated serine/threonine kinase 1 (MAST1) is a central driver of cisplatin resistance in human cancers. However, the molecular mechanism regulating MAST1 levels in cisplatin-resistant tumors is unknown. Through a proteomics screen, we identified the heat shock protein 90 B (hsp90B) chaperone as a direct MAST1 binding partner essential for its ...
stabilization. Targeting hsp90B sensitized cancer cells to cisplatin predominantly through MAST1 destabilization. Mechanistically, interaction of hsp90B with MAST1 blocked ubiquitination of MAST1 at lysines 317 and 545 by the E3 ubiquitin ligase CHIP and prevented proteasomal degradation. The hsp90B-MAST1-CHIP signaling axis and its relationship with cisplatin response were clinically validated in cancer patients. Furthermore, combined treatment with a hsp90 inhibitor and the MAST1 inhibitor lestaurtinib further abrogated MAST1 activity and consequently enhanced cisplatin-induced tumor growth arrest in a patient-derived xenograft model. Our study not only uncovers the regulatory mechanism of MAST1 in tumors but also suggests a promising combinatorial therapy to overcome cisplatin resistance in human cancers.
Mesh Terms:
A549 Cells, Amino Acid Substitution, Animals, Binding Sites, Cell Line, Tumor, Cisplatin, Drug Resistance, Neoplasm, Female, Gene Knockdown Techniques, HEK293 Cells, HSP90 Heat-Shock Proteins, Humans, Mice, Mice, Nude, Microtubule-Associated Proteins, Mutagenesis, Site-Directed, Proteasome Endopeptidase Complex, Protein Stability, Protein-Serine-Threonine Kinases, Ubiquitination, Xenograft Model Antitumor Assays
J. Clin. Invest.
Date: Dec. 01, 2018
Download Curated Data For This Publication
222916
Switch View:
  • Interactions 9